ロード中...
Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4861375/ https://ncbi.nlm.nih.gov/pubmed/27107001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0108 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|